Category: Ondine Biomedical Inc

Carolyn Cross Tells Her Remarkable Story To Chatelaine Magazine

In the same way fate seems to keep knocking on Carolyn’s door, she felt the benefits of her determination first-hand. After the crash, Carolyn was taken to Vancouver General Hospital (VGH), the first major institution to roll out Ondine’s technology. Like all patients undergoing surgery, she was zapped clean by Ondine’s laser.

Ondine Biomedical Inc Proudly Supports The PanAmerican PDT Association

Ondine Biomedical Inc. is a proud supporter of the mission and goals of the PanAmerican Photodynamic Therapy Association. Launched last month, the Association’s purpose is to galvanize the basic science and expertise of photodynamic therapy in the Americas. This will help encourage the study and practice of PDT in the treatment of animal and human diseases.

Many of you may not know that photodynamic therapy has been around for centuries. In fact, the earliest recorded treatment using a photosensitizing agent and a light source occurred in ancient Egypt over 3,000 years ago. Vegetable and plant substances were used as photosensitizers and sunlight was used as the light source. Patients suffering from skin diseases such as vitiligo had the photosensitizers topically applied to the damaged area, and the resulting photochemical reaction restored their tissue to a healthier state. In some cases, it even helped repigment their skin to its normal color.

Read More

Ondine Study Shows Reduction of Endotracheal Tube Biofilm Using Photodisinfection

Ventilator-associated pneumonia is one of the most common and deadliest forms of healthcare-associated infections.  In the U.S alone, more than one million patients in healthcare facilities require mechanical ventilation every year. Up to 1 in 4 of these patients are reported to develop ventilator-associated pneumonia and up to half of them will die.1

Antimicrobial photodynamic therapy (aPDT), commonly known as Photodisinfection, is a non-invasive technique that used to study the reduction of biofilm in the lumen of an endotracheal tube. When patients undergo mechanical ventilation, an endotracheal tube is inserted into their throat to assist with breathing. This tube has long been recognized as a major factor in a patient’s risk for developing biofilm infections. For patients that require mechanical ventilation, such as those in ICUs, the biofilm can dislodge from the endotracheal tube and enter the lungs directly, often resulting in difficult-to-treat pneumonia.

Read More

Ondine Congratulates Dr. Bryon Bhagwandin For Presenting His Research At The International AIDS Society Conference 2011

The use of Photodisinfection to disinfect the birth canal is a novel approach that can bypass the stigma associated with HIV treatment and any reliance on patient compliance.

Ondine is pleased to congratulate Dr. Bryon Bhagwandin of Vitalwave™ on the publication of his abstract at the International AIDS Society (IAS) Conference. This is an important accomplishment as it highlights the need to develop new approaches in preventing mother-to-child HIV transmission.

A higher vaginal HIV viral load has been independently associated with a higher risk of transmission. Dr. Bhagwandin’s study evaluated the use of antimicrobial Photodynamic Therapy (aPDT), also known as Photodisinfection, as a means to reduce the vaginal viral load of pregnant women infected with HIV/AIDS. In 2008, more than 1.4 million pregnant women were living with this disease. An additional 430,000 children had been infected through mother-to-child transmission.

Read More

Working at Ondine: A Career Leading To A Harvard MBA

December 14, 2010 was a really special day for me. I was in my office when I got the news – I had been accepted to Harvard Business School’s MBA program. Now, as my time at Ondine comes to an end, I’ve been asked to recount my story, and how I got to the enviable position of being able to leave a job that I love for an unbelievable opportunity.

I began at Ondine in January of 2008 after returning from a backpacking trip around Western Europe. I had secured the internship the summer beforehand, and viewed it as the perfect opportunity. I had always been interested in business, but I was convinced that I would be attending dental school, having written the entrance examinations during my undergraduate degree. Ondine, having a commercially available dental product, was the hybrid I was looking for. So, armed with only my UBC degree in Cell Biology and Genetics, I set off to see what business was all about. Read More

Ondine CEO, Carolyn Cross, Inducted Onto The Board of the International Photodynamic Association

“We have spent the last 70 years using and misusing antibiotics to treat and prevent common infectious diseases…It is therefore imperative that non-antibiotic solutions to fight infections are developed in order to preserve the next generation of effective medicine.”

Carolyn Cross Inducted Onto Board of IPA

Our CEO has done it again. Two weeks after being featured in the Vancouver Sun Newspaper, Ms. Cross has now been inducted onto the Board of the International Photodynamic Association (IPA). Founded in 1986, the IPA brings together the most distinguished international clinicians and scientists involved in researching and developing photodynamic therapy. Ms. Cross will help raise awareness about the benefits of this technology and help bring it to the forefront of medicine.

We are very pleased to share this announcement with all of you today. Ms. Cross has been with Ondine for over a decade and was one of the initial founders and financial supporters of our company. Under her leadership, Ondine has developed a rapid R & D program and is now seen as one of the world’s most renowned group of experts on photodynamic therapy and photodisinfection. Read More

Ondine’s 100th Post – An Exciting Blogging Milestone!

Today, we celebrate our first blogging milestone – our 100th post. It’s incredible to see how far we have come, and exciting to imagine where we soon will be. You, the readers and followers of Ondine’s blogs, have played the central role in getting us here; your encouraging words, insightful comments, and guest blog posts have helped us tremendously throughout this process. Thank you so much.

Our goal has always been to make important points in bite-sized, digestible sound bites for today’s fast paced world. Our first one hundred posts have helped lay the foundation for this, and our next steps involve creating more engaging, relevant and compelling content. This will come in the form of videos, graphics, testimonials and case studies from the field.

Read More

Ondine Chairman & CEO, Carolyn Cross, Featured In Vancouver Sun Newspaper

Carolyn Cross, Chairman & CEO of Ondine Biomedical Inc, understands too well the importance of supporting women in business.  This week, the Vancouver Sun Newspaper highlighted her involvement & support for this week’s Women Presidents’ Organization (WPO) International Conference. This is a unique event that connects highly successful women from around the world in promoting the advancement of women across all industries. The WPO is an exclusive membership organization for women presidents of multimillion-dollar companies. Collectively, members of the WPO have 24,000 years in business, generate $14 billion in annual revenues, and employ 105,000 employees.

Carolyn Cross, Chairman & CEO of Ondine Biomedical Inc, was featured in today's Vancouver Sun Newspaper

Read More

MRSAid™ & VGH Infection Control Project Featured on Canadian National News!

Last Friday, we announced an innovative partnership with Vancouver General Hospital (VGH), one of Canada`s largest hospitals. Today, we are very excited to have this partnership featured on Global News.

MRSAidTM is a non-antibiotic therapy designed to eliminate bacteria in the noses of patients during high infection risk times. Pathogenic bacteria such as Staphylococcus aureus and MRSA can significantly increase the risk of a patient developing serious infections after surgery. As part of our partnership with VGH, MRSAidTM will be used on patients undergoing cardiac, spinal, breast reconstruction, thoracic, neurological, and orthopaedic surgeries. We are very excited to be working with the leaders in infection control at VGH. For more information on MRSAidTM, please visit www.mrsaid.com. Also, connect with us on TwitterFacebook, we`ll be happy to respond to any of your comments and questions.

Ondine To Participate in Vancouver General Hospital Infection Control Project

MRSAid product by Ondine Biomedical

World Health Day is celebrated on the 7th of April every year to mark the establishment of the World Health Organization (WHO). Each year, the WHO selects a key health issue and encourages people from around the world to hold events and promote actions that will improve health. It is very fitting for Ondine then that this year’s World Health Day theme is “Combating Drug Resistance.” We have spent the last 70 years using and misusing antibiotics to treat and prevent common infectious diseases. Today, we have entered an era where bacteria have developed the ability to become resistant to most antibiotics, rendering them almost useless. It is therefore imperative that non-antibiotic solutions to fight infections are developed in order to preserve the next generation of effective medicine. Read More

Related Posts Plugin for WordPress, Blogger...

Staypressed theme by Themocracy